Arcutis Biotherapeutics
ARQT
ARQT
115 hedge funds and large institutions have $914M invested in Arcutis Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 52 increasing their positions, 19 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
8% more funds holding
Funds holding: 106 → 115 (+9)
2% more capital invested
Capital invested by funds: $895M → $914M (+$18.7M)
0.44% less ownership
Funds ownership: 95.89% → 95.44% (-0.44%)
Holders
115
Holding in Top 10
5
Calls
$5.68M
Puts
$2.08M
Top Buyers
| 1 | +$19.7M | |
| 2 | +$9.89M | |
| 3 | +$9.27M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.17M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.7M |
Top Sellers
| 1 | -$20.9M | |
| 2 | -$10.7M | |
| 3 | -$2.87M | |
| 4 |
Axa
Paris,
France
|
-$2.8M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$2.46M |